drugset / Trial / NCT05107739
A Study of DeTIL-0255 in Adults With Advanced Malignancies
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a first-in-human Phase 1 multicenter, open-label oncology study designed to evaluate the safety and efficacy of NX-DeTIL-0255-201 in patients with advanced malignancies.
Timeline
- Start
- 2021-12-22
- Primary completion
- 2023-05-09
- Completion
- 2023-05-09
Outcome
Outcome not reported
Stopped (Business): “Sponsor Decision”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DeTIL-0255 | Cell therapy | — | — |